Cargando…

High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis

BACKGROUND: Lymphoma-associated macrophages (LAMs) are key components in the lymphoma microenvironment, which may impact disease progression and response to therapy. There are two major subtypes of LAMs, CD68+ M1 and CD163+ M2. M2 LAMs can be transformed from M1 LAMs, particularly in certain diffuse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Philippa, Yuan, Ji, Ahmed, Fahad Shabbir, McHenry, Austin, Fu, Kai, Yu, Guohua, Cheng, Hongxia, Xu, Mina L., Rimm, David L., Pan, Zenggang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435777/ https://www.ncbi.nlm.nih.gov/pubmed/34527580 http://dx.doi.org/10.3389/fonc.2021.701492

Ejemplares similares

CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma
por: Harris, Jonathan A, et al.
Publicado: (2012)

The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma
por: Kong, Ling-Qun, et al.
Publicado: (2013)

Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy–treated mantle cell lymphoma
por: Nikkarinen, Anna, et al.
Publicado: (2023)

The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma
por: Salmi, Satu, et al.
Publicado: (2019)

Prophylaxis of decidual CD68(+)/CD163(+) macrophage disbalance in extracorporeal fertilized women
por: Likhachov, Volodymyr, et al.
Publicado: (2023)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancers
por: Pelekanou, Vasiliki, et al.
Publicado: (2018)

CD68- and CD163-positive tumor-associated macrophages in triple negative cancer of the breast
por: Jamiyan, Tsengelmaa, et al.
Publicado: (2020)

Relationship of Tumor-Associated Macrophage Population Detected by CD68 PG-M1, CD68 KP1, and CD163 with Latent EBV Infection and Prognosis in Classical Hodgkin Lymphoma
por: Mavili, Hanife Seda, et al.
Publicado: (2021)

Prognostic and predictive value of CD163 expression and the CD163/CD68 expression ratio for response to adjuvant chemotherapy in patients with surgically resected lung squamous cell carcinoma
por: Yanagawa, Naoki, et al.
Publicado: (2023)

Soluble ectodomain CD163 and extracellular vesicle-associated CD163 are two differently regulated forms of ‘soluble CD163’ in plasma
por: Etzerodt, Anders, et al.
Publicado: (2017)

Clinical Significance of CD163+ and CD68+ Tumor-associated Macrophages in High-risk HPV-related Cervical Cancer
por: Chen, Xiao-Jing, et al.
Publicado: (2017)

Tumor-Associated CD68(+), CD163(+), and MARCO(+) Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
por: Jeremiasen, Martin, et al.
Publicado: (2020)

PPAR-Gamma Agonist Pioglitazone Reduced CD68+ but Not CD163+ Macrophage Dermal Infiltration in Obese Psoriatic Patients
por: Yemchenko, Ya. O., et al.
Publicado: (2020)

High Infiltration of CD68(+)/CD163(−) Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma
por: Svensson, Maria C., et al.
Publicado: (2022)

Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma
por: Zhang, Xin‐Yu, et al.
Publicado: (2016)

Relationship Between sCD163 and mCD163 and Their Implication in the Detection and Typing of Leprosy
por: Farag, Azza Gaber Antar, et al.
Publicado: (2020)

Elevated CD163(+)/CD68(+) Ratio at Tumor Invasive Front is Closely Associated with Aggressive Phenotype and Poor Prognosis in Colorectal Cancer
por: Yang, Chaogang, et al.
Publicado: (2019)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?
por: Bravaccini, Sara, et al.
Publicado: (2019)

Differential association of CD68(+) and CD163(+) macrophages with macrophage enzymes, whole tumour gene expression and overall survival in advanced melanoma
por: Tremble, Liam Friel, et al.
Publicado: (2020)

CD68- and CD163-positive tumor infiltrating macrophages in non-metastatic breast cancer: a retrospective study and meta-analysis
por: Ni, Chao, et al.
Publicado: (2019)

Bone marrow expression of CD68/CD163 macrophages, IL‐17 and FOXP3 cells in aplastic anemia and their relation to prognosis
por: Vaht, Krista, et al.
Publicado: (2022)

Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody
por: Li, Ziduo, et al.
Publicado: (2020)

CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma
por: Cuccaro, Annarosa, et al.
Publicado: (2016)

Lung Expression of Macrophage Markers CD68 and CD163, Angiotensin Converting Enzyme 2 (ACE2), and Caspase-3 in COVID-19
por: Ziablitsev, Denis S., et al.
Publicado: (2023)

CD24 Is a Potential Immunotherapeutic Target for Mantle Cell Lymphoma
por: Freile, Jimena Álvarez, et al.
Publicado: (2022)

Clinical Significance of Soluble Hemoglobin Scavenger Receptor CD163 (sCD163) in Sepsis, a Prospective Study
por: Feng, Lin, et al.
Publicado: (2012)

Soluble CD163 and CD163 Expression on Monocytes Associated with Chronic Hepatitis B Inflammation and HBsAg Loss
por: Xie, Peilin, et al.
Publicado: (2022)

CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients
por: Ahmed, Huda Al Sayed, et al.
Publicado: (2019)

Prognostic impact of soluble CD163 in patients with diffuse large B-cell lymphoma
por: Vajavaara, Heli, et al.
Publicado: (2021)

Clinicopathologic Features and Treatment of CD10-Positive Mantle Cell Lymphoma: A Case Report and Review of Literature
por: Hino, Christopher, et al.
Publicado: (2022)

Soluble CD 163: A novel biomarker
por: Ahuja, Rajeev B.
Publicado: (2011)

CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation
por: Sekerkova, Alena, et al.
Publicado: (2014)

Prognostic Role of CD68(+) and CD163(+) Tumour-Associated Macrophages and PD-L1 Expression in Oral Squamous Cell Carcinoma: A Meta-Analysis
por: Chohan, Mohammed Haseeb, et al.
Publicado: (2023)

CD10-positive mantle cell lymphoma: clinicopathologic and prognostic study of 30 cases
por: Xu, Jie, et al.
Publicado: (2017)

CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
por: Fuhr, Viktoria, et al.
Publicado: (2022)

In vitro Phenotype Induction of Circulating Monocytes: CD16 and CD163 Analysis
por: Karsulovic, Claudio, et al.
Publicado: (2021)

EZH2 expression is associated with inferior overall survival in mantle cell lymphoma
por: Martinez-Baquero, Diana, et al.
Publicado: (2021)

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium
por: Stevens, Wendy B.C., et al.
Publicado: (2017)

Local production of soluble CD163 in the spondyloarthropathic joint
por: Baeten, D, et al.
Publicado: (2003)

Targeting of CD163(+) Macrophages in Inflammatory and Malignant Diseases
por: Skytthe, Maria K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qcjiv8n3faqlmgbmha9urnqn0p